Spravato® (esketamine) is an FDA-approved treatment available for adults with treatment-resistant depression who have not found adequate relief with traditional antidepressant medications. Unlike conventional antidepressants that primarily target serotonin, Spravato works through the brain's glutamate system, offering a different approach to treating depression.
Spravato is provided in a safe, comfortable clinical setting where patients are monitored after each treatment session.
Our team works closely with each patient to determine whether Spravato may be an appropriate option as part of a personalized mental health treatment plan designed to support long-term emotional wellness.
